MedTrace Logo

Stivarga Regulatory Post-Marketing Surveillance Study in Korea

NCT02106858 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 316

Last updated 2023-07-24

No results posted yet for this study

Summary

To investigate and collect post-marketing data on the safety of Stivarga in real world practice in its registered indication(s) as required by Health Authority.

Conditions

  • Colorectal Neoplasms

Interventions

DRUG

Regorafenib (Stivarga,BAY73-4506)

Patients treated by Physician with Stivarga under approved local prescriptions

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-25
Primary Completion
2019-05-07
Completion
2019-05-07

Countries

  • South Korea

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02106858 on ClinicalTrials.gov